Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvometinib Observational Cohort in Adult LCH and Histiocytic Neoplasms Using 68Ga-FAPI PET/CT
ChiCTR2600125932Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of luvometinib in Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and histiocytic disease, sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate (ORR) based on PRC efficacy evaluation criteria. Started Jun 2026; status: recruiting.
02
Drugs
luvometinib
03
Conditions
Langerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)histiocytic disease
Beyond the preview
Go deeper on ChiCTR2600125932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125932.